Advertisement

Search Results

Advertisement



Your search for Maura L. Gillison, MD, PhD matches 12 pages

Showing 1 - 12


2020 Class of Giants of Cancer Care Announced

The Eighth Annual Giants of Cancer Care class of inductees was recently announced by OncLive, a multimedia resource focused on providing oncology professionals with relevant information on patient care. The virtual awards ceremony will be held on November 5 at 7.30 PM EST and will be available...

head and neck cancer
immunotherapy

Immunotherapy for Head/Neck Squamous Cell Carcinoma: Questions Raised by KEYNOTE-048

There is a new first-line treatment option for patients with newly diagnosed, recurrent, or metastatic head and neck squamous cell carcinoma. As reported by Burtness et al in The Lancet, pembrolizumab improved overall survival vs the standard-of-care regimen of cetuximab and platinum-based...

head and neck cancer

HPV-Positive Oropharyngeal Cancer Burden Rising Among White Men in the United States

White men older than age 65 will have the greatest burden of oropharyngeal cancer by the year 2030, according to Maura L. Gillison, MD, PhD, Professor and Endowed Chair at MD Anderson Cancer Center in Houston. But there is some good news, she said at the 2019 Winship Cancer Institute of Emory...

head and neck cancer

Maura L. Gillison, MD, PhD, Pioneer in HPV-Related Head and Neck Cancer, Has Often Changed Lanes in Her Career

When The ASCO Post asked physician-scientist Maura L. Gillison, MD, PhD, where she was from, she answered, “North America.” Actually, she was born in Canada, but her father worked for a large international company, so the family moved regularly through Canada, the United States, and Mexico. “I...

head and neck cancer

HPV DNA and Outcomes After Primary Treatment for Oral and Oropharyngeal Squamous Cell Carcinomas

In a two-institution study reported in JAMA Oncology, Fakhry et al found that persistent detection of tumor-type human papillomavirus (HPV) DNA after primary treatment for oral and oropharyngeal squamous cell carcinomas was associated with poorer outcomes. Study Details The prospective study...

issues in oncology

HPV Vaccination and Oral HPV Infections in Young Adults in the United States

In a study reported in the Journal of Clinical Oncology, Chaturvedi et al found that whereas prophylactic human papillomavirus (HPV) vaccination has reduced the incidence of oral HPV infection in young adults compared with no vaccination, low uptake of the vaccine has resulted in a modest overall...

head and neck cancer
issues in oncology

Maura L. Gillison, MD, PhD, on HPV and the Value of the Vaccine

Maura L. Gillison, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses her findings on the impact of prophylactic human papillomavirus vaccination on oral HPV infections among young adults in the United States. (Abstract 6003)

head and neck cancer

Rates of Oral HPV Infection Plummet After Vaccination

Vaccination against the human papillomavirus (HPV) reduced the risk of acquiring oral HPV infections by 88%, in one of the first large studies to explore vaccination’s impact in the oropharynx. The study will be presented at the 2017 ASCO Annual Meeting, and the findings were released in advance of ...

gynecologic cancers

ASCO 2017: HPV Vaccination May Reduce Oral HPV Infections but Is Still Underutilized

In one of the first large studies to explore the possible impact of human papillomavirus (HPV) vaccination on oral HPV infections, researchers found it may confer a high degree of protection. The study of young adults in the United States showed that the prevalence of high-risk HPV infection was...

head and neck cancer

Study Finds Nivolumab Improves Survival vs Standard Therapy in Recurrent Squamous Cell Carcinoma of the Head and Neck

In the phase III CheckMate 141 trial reported in The New England Journal of Medicine, Ferris et al found that nivolumab (Opdivo) increased overall survival vs standard therapies in patients with recurrent platinum-refractory squamous cell carcinoma of the head and neck. Study Details In this...

head and neck cancer

AACR 2016: Nivolumab Improved Survival for Patients With Head and Neck Squamous Cell Carcinoma

For the latest information on CheckMate-141, click here, here, or here. Treatment with the immunotherapeutic nivolumab (Opdivo) improved survival for patients with recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum-based chemotherapy compared with...

head and neck cancer

HPV-Positive Oropharyngeal Cancer Associated With Higher Overall Survival Rate After Progression Than HPV-Negative Disease

A retrospective analysis of patients with oropharyngeal cancer with recurrence of disease after primary therapy in the Radiation Therapy Oncology Group (RTOG) studies 0129 and 0522 found that human papillomavirus (HPV)-positive patients had a higher overall survival rate than HPV-negative patients, ...

Advertisement

Advertisement



Advertisement